High-Flow Nasal Cannula Oxygen Delivery During Bronchoscopy With Bronchoalveolar Lavage in Hypoxemic Patients: Analysis of 16 Cases

CHEST Journal ◽  
2015 ◽  
Vol 148 (4) ◽  
pp. 824A
Author(s):  
Kyungchan Kim ◽  
Daesung Hyun ◽  
Sangwoo Shim
2014 ◽  
Vol 52 (5) ◽  
pp. 310-314 ◽  
Author(s):  
Kazuya Miyagi ◽  
Shusaku Haranaga ◽  
Futoshi Higa ◽  
Masao Tateyama ◽  
Jiro Fujita

2021 ◽  
Author(s):  
Takahiro Takazono ◽  
Kazuko Yamamoto ◽  
Ryuta Okamoto ◽  
Masato Tashiro ◽  
Shimpei Morimoto ◽  
...  

ABSTRACTRationaleAerosol dispersion under various oxygen delivery modalities, including high flow nasal cannula, is a critical concern for healthcare workers who treat acute hypoxemic respiratory failure during the coronavirus disease 2019 pandemic. Effects of surgical masks on droplet and aerosol dispersion under oxygen delivery modalities are not yet clarified.ObjectivesTo visualize and quantify dispersion particles under various oxygen delivery modalities and examine the protective effect of surgical masks on particle dispersion.MethodsThree and five healthy men were enrolled for video recording and quantification of particles, respectively. Various oxygen delivery modalities including high flow nasal cannula were used in this study. Particle dispersions during rest breathing, speaking, and coughing were recorded and automatically counted in each condition and were evaluated with or without surgical masks.Measurements and Main ResultsCoughing led to the maximum amount and distance of particle dispersion, regardless of modalities. Droplet dispersion was not visually increased by oxygen delivery modalities compared to breathing at room air. With surgical masks over the nasal cannula or high-flow nasal cannula, droplet dispersion was barely visible. Oxygen modalities did not increase the particle dispersion counts regardless of breathing pattens. Wearing surgical masks significantly decreased particle dispersion in all modalities while speaking and coughing, regardless of particle sizes, and reduction rates were approximately 95 and 80-90 % for larger (> 5 μm) and smaller (> 0.5 μm) particles, respectively.ConclusionsSurgical mask over high flow nasal canula may be safely used for acute hypoxemic respiratory failure including coronavirus disease 2019 patients.Subject Category List4.13 Ventilation: Non-Invasive/Long-Term/Weaning*This article has an online data supplement, which is accessible from this issue’s table of content online at www.atsjournals.org.


2016 ◽  
Vol 105 (8) ◽  
pp. e368-e372 ◽  
Author(s):  
Gregorio P. Milani ◽  
Anna M. Plebani ◽  
Elisa Arturi ◽  
Danila Brusa ◽  
Susanna Esposito ◽  
...  

2019 ◽  
Vol 6 (2) ◽  
pp. 460
Author(s):  
Amrish Patel ◽  
Jitesh Atram ◽  
H. S. Dumra ◽  
Mansi Dandnaik ◽  
Gopal Raval

Background: High-flow nasal cannula (HFNC) oxygen therapy is carried out using an air/oxygen blender, active humidifier, single heated tube, and nasal cannula. It is an oxygen delivery system which uses air blender to deliver accurate oxygen concentration to the patient from 21% to 100% at desired temperature. It can be administered via wide bore nasal cannula or to the tracheostomy tube via connector. It can give upto 60L/min flow hence can generate positive end expiratory pressure between 2 to 7 cmH20. By providing humidified oxygen along with the high flow rates it satisfies air hunger and reduces work of breathing for the patient.Methods: This is a retrospective observational study. Patients with persistent hypoxia in spite of conventional oxygen therapy were treated with HFNC. Patients with possible need for immediate invasive ventilator support were excluded. Clinical respiratory parameters and oxygenation were compared under conventional and HFNC oxygen therapy.Results: Thirty patients, aged more than 18 years admitted in intensive respiratory care unit with acute hypoxemic respiratory failure from June 2017 to January 2018 were included in the study. Study period was of 6 months. Etiology of acute respiratory failure (ARF) was mainly pneumonia (n = 17), interstitial lung disease (n = 5), bronchial asthma (n=3) and others (n = 5). There was statistically significant reduction in respiratory rate (29.40 before Vs 23.50 after; P- <0.0001) and significant improvement in comfort level of the patient after HFNC therapy. Median duration of HFNC was 48 hrs (24-360) hours. Five patients were intubated later on and 4 died in the intensive care unit.Conclusions: Use of HFNC in patients with persistent ARF was associated with significant and sustained improvement of clinical parameters (respiratory rate). It can be used comfortably for prolonged periods.


Sign in / Sign up

Export Citation Format

Share Document